This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • A Study of Polatuzumab Vedotin (DCDS4501A) in Comb...
Clinical trial

A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Patients With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

Read time: 1 mins
Last updated:2nd Oct 2014

This study is a multicenter, open-label study of polatuzumab vedotin administere d by intravenous (IV) infusion in combination with standard doses of bendamustin e (B) and rituximab (R) or obinutuzumab (G) in patients with relapsed or refract ory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL). The study comprises two stages: a Phase 1b dose-escalation stage and a Phase 2 stage. The anticipated time on treatment is 18-24 weeks.

Category Value
Study start date 2014-10-02

View full details